Title of Invention: Acrylamide compounds and the use thereof Abstract: The invention relates to acrylamide compounds of Formula I mentioned below. The invention is also directed to the use compounds of Formula I to treat or prevent a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain. Detailed Description: Part general_description_paragraphs: Part CROSS REFERENCE TO RELATED APPLICATIONS: This application is a national phase application under 35 U.S.C. 371 based on International Application No. PCT/JP2010/056404, filed Apr. 2, 2010, which claims the benefit of U.S. Provisional Application No. 61/166,206, filed Apr. 2, 2009, the entire content of both of which is hereby incorporated by reference. Part TECHNICAL FIELD: This invention is in the field of medicinal chemistry. The invention relates to acrylamide compounds and the use of these compounds as blockers of calcium (Ca2+) channels. Part BACKGROUND ART: Calcium ions play fundamental roles in the regulation of many cellular processes. It is therefore essential that their intracellular levels be maintained under strict, yet dynamic control (NPL1). Voltage-gated calcium channels (VGCC) serve as one of the important mechanisms for fast calcium influx into the cell. Calcium channels are hetero-oligomeric proteins consisting of a pore-forming subunit (α1), which is able to form functional channels on its own in heterologous expression systems, and a set of auxiliary or regulatory subunits. Calcium channels have been classified based on their pharmacological and/or electrophysiological properties. The classification of voltage-gated calcium channels divides them into three groups: (i) high voltage-activated (HVA) channels, which include L-, N-, P-, and Q-types; (ii) intermediate (IVA) voltage-activated R-type channels; and (iii) low voltage-activated (LVA) T-type channels (NPL1). Voltage-gated calcium channels (VGCC) are also known as voltage-dependent calcium channels (VDCC) or voltage-sensitive calcium channels (VSCC). Voltage-sensitive calcium channels (VSCC) regulate intracellular calcium concentration, which affects various important neuronal functions such as cellular excitability, neurotransmitter release, hormone secretion, intracellular metabolism, neurosecretory activity and gene expression (NPL2). N-type channels are found mainly in central and peripheral neurons, being primarily located on presynaptic nerve terminals. These channels regulate the calcium flux required for depolarization-evoked release of a transmitter from synaptic endings. The transmission of pain signals from the periphery to the central nervous system (CNS) is mediated by N-type calcium channels located in the spinal cord (NPL3). The six types of calcium channels (i.e., L, N, P, Q, R, and T) are expressed throughout the nervous system (NPL4). Voltage-sensitive calcium channels of the N-type exist in the superficial laminae of the dorsal horn and are thought to modulate nociceptive processing by a central mechanism. Blockade of the N-type calcium channel in the superficial dorsal horn modulates membrane excitability and inhibits neurotransmitter release, resulting in pain relief. Wallace (NPL4) suggests that based on animal models, N-type calcium channel antagonists have a greater analgesic potency than sodium channel antagonists. N-type calcium channel blockers have usefulness for neuroprotection and analgesia. Ziconotide, which is a selective N-type calcium channel blocker, has been found to have analgesic activity in animal models and neuroprotective activity in focal and global ischemia models (NPL3). Examples of known calcium channel blockers include flunarizine, fluspirilene, cilnipide, PD 157767, SB-201823, SB-206284, NNC09-0026, and PD 151307 (NPL2). Blockade of N-type channels can prevent and/or attenuate subjective pain as well as primary and/or secondary hyperalgesia and allodynia in a variety of experimental and clinical conditions (NPL5). N-type voltage-gated calcium channels (VGCC) play a major role in the release of synaptic mediators such as glutamate, acetylcholine, dopamine, norepinephrine, gamma-aminobutyric acid (GABA) and calcitonin gene-related peptide (CGRP). Inhibition of voltage-gated L-type calcium channels has been shown to be beneficial for neuroprotection (NPL3). However, inhibition of cardiac L-type calcium channels can lead to hypotension. It is believed that a rapid and profound lowering of arterial pressure tends to counteract the neuroprotective effects of L-type calcium channel blockers. A need exists for antagonists that are selective for N-type calcium channels over L-type calcium channels to avoid potential hypotensive effects. Similar compounds to those of the present invention are described in the following documents but the structures of these compounds are different from those of the present invention: PTL1, PTL2, PTL3, PTL4, PTL5, PTL6, PTL7, PTL8, PTL9, PTL10, NPL6, NPL7, NPL8, NPL9, NPL10, PTL11, NPL11, NPL12, PTL12, PTL13, PTL14, PTL15, PTL16, PTL17, PTL18, PTL19, PTL20, PTL21, PTL22 and PTL23. Part CITATION LIST: Part Patent Literature: {PTL 1} WO 2007/071035 A1 {PTL 2} WO 2006/024160 A1 {PTL 3} WO 2007/125398 A2 {PTL 4} WO 2007/002361 A2 {PTL 5} WO 2002/100833 A1 {PTL 18} WO 2007/110449 A1 {PTL 19} WO 2007/118854 A1 {PTL 20} WO 2008/008398 A2 {PTL 21} WO 2008/150447 A1 {PTL 22} WO 2008/150470 A1 {PTL 23} WO 2009/151152 A1 {PTL 24} U.S. Pat. No. 6,136,839 A Part Non Patent Literature: {NPL 1} Davila, H. M., Annals of the New York Academy of Sciences, pp. 102-117 (1999) {NPL 2} Hu et al., Bioorganic & Medicinal Chemistry 8:1203-1212 (200) {NPL 3} Song et al., J. Med. Chem. 43:3474-3477 (2000) {NPL 4} Wallace, M. S., The Clinical Journal of Pain 16:580-585 (2000) {NPL 5} Vanegas, H. et al., Pain 85:9-18 (2000) {NPL 6} Journal of Organic Chemistry 72(3): 1005-1008 (2007), {NPL 7} European Journal of Pharmacology 563(1-3): 224-232 (2007), {NPL 8} Current Opinion in Drug Discovery & Development 9(4): 516-524 (2006), {NPL 9} Journal of Pharmacology and Experimental Therapeutics 317(1): 244-250 (2006), {NPL 10} Biochemical and Biophysical Research Communications 339(4): 1217-1223 (2006) {NPL 11} Journal of Medicinal Chemistry 49(4): 1388-1396 (2006), {NPL 12} Molecular Pharmacology 4(1): 44-52 (1968) {NPL 13} Design of Prodrugs, H. Bundgaard ed., Elsevier (1985) {NPL 14} “Drug and Enzyme Targeting, Part A,” K. Widder et al. eds., Vol. 112 in Methods in Enzymology, Academic Press (1985) {NPL 15} Bundgaard, “Design and Application of Prodrugs,” Chapter 5 (pp. 113-191) in A Textbook of Drug Design and Development, P. Krogsgaard-Larsen and H. Bundgaard eds., Harwood Academic Publishers (1991) {NPL 16} Bundgaard et al., Adv. Drug Delivery Revs. 8:1-38 (1992) {NPL 17} Bundgaard et al., J. Pharmaceut. Sci. 77:285 (1988) {NPL 18} Kakeya et al., Chem. Pharm. Bull. 32:692 (1984) {NPL 19} Filer, Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987) {NPL 20} M. Caira et al., J. Pharmaceut. Sci., 93(3):601-611 (2004) {NPL 21} E. C. van Tonder et al., AAPS Pharm. Sci. Tech., 5(1):Article 12 (2004) {NPL 22} A. L. Bingham et al., Chem. Commun.: 603-604 (2001) {NPL 23} Brower, Nature Biotechnology 2000; 18: 387-391 {NPL 24} Levine, Inflammatory Pain, In: Textbook of Pain, Wall and Melzack eds., 3rd ed., 1994 {NPL 25} Proc. Natl. Acad. Sci. U.S.A 89: 5058-5062 (1992) {NPL 26} FEBS Lett. 291: 253-258 (1991) {NPL 27} J. Biol. Chem. 268: 12359-12366 (1993) {NPL 28} Proc. Natl. Acad. Sci. U.S.A. 89: 3251-3255 (1992) {NPL 29} J. Biol. Chem. 265: 17786-17791 (1990) {NPL 30} Neuron 18: 153-166 (1997) {NPL 31} Hamill et al., Pfluegers Arch. 391: 85-100 (1981) {NPL 32} Hunskaar, S., O. B. Fasmer, and K. Hole, J. Neurosci. Methods 14: 69-76 (1985) {NPL 33} Kim and Chung, Pain 50: 355-363 (1992) {NPL 34} Biochemistry & Behavior 31: 451-455 (1988) {NPL 35} Paul A. Insel, Analgesic Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout, in Goodman & Gilman's The Pharmacological Basis of Therapeutics 617-57 (Perry B. Molinhoff and Raymond W. Ruddon eds., 9th ed 1996) {NPL 36} Glen R. Hanson, Analgesic, Antipyretic and Anti Inflammatory Drugs in Remington: The Science and Practice of Pharmacy Vol II 1196-1221 (A. R. Gennaro ed. 19th ed. 1995) Part SUMMARY OF INVENTION: The present invention is related to acrylamide compounds represented by Formula I below, and the pharmaceutically acceptable salts and solvates thereof, and the use of these compounds as blockers of calcium (Ca2+) channels. Certain compounds of Formula I show selectivity as N-type calcium channel blockers. The invention is also related to treating or preventing a disorder responsive to the blockade of calcium channels in a mammal suffering from excess activity of said channels by administering an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, as described herein. Specifically, the invention is related to treating or preventing a disorder responsive to the blockade of N-type calcium channels in a mammal suffering from excess activity of said channels by administering an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, as described herein. One aspect of the present invention is directed to novel compounds of Formula I and their pharmaceutically acceptable salts and solvates. Another aspect of the present invention is directed to the use of the novel compounds of Formula I, and their pharmaceutically acceptable salts and solvates as blockers of N-type calcium channels. A further aspect of the present invention is to provide a pharmaceutical composition useful for treating or preventing a disorder responsive to the blockade of calcium ion channels, especially N-type calcium ion channels, said pharmaceutical composition containing an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, in a mixture with one or more pharmaceutically acceptable carriers. Also, an aspect of the invention is to provide a method for treating or preventing a disorder responsive to the blockade of calcium ion channels, especially N-type calcium ion channels, in a mammal, wherein said method comprises administering to the mammal an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof. Also, an aspect of the invention is to provide use of a compound of Formula I, or a pharmaceutically acceptable salt, or a solvate thereof in the manufacture of a medicament for treating or preventing a disorder responsive to the blockade of calcium ion channels, especially N-type calcium channels, in a mammal. Also, an aspect of the invention is to provide a compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, for use in a method for treating or preventing a disorder responsive to the blockade of calcium ion channels, especially N-type calcium channels, in a mammal, wherein said method comprises administering to the mammal an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof. A further aspect of the invention is to provide a pharmaceutical composition useful for modulating calcium channels, especially N-type calcium channels, said pharmaceutical composition containing an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, in a mixture with one or more pharmaceutically acceptable carriers. Also, an aspect of the invention is to provide a method of modulating calcium channels, especially N-type calcium channels, in a mammal, wherein said method comprises administering to the mammal an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof. Also, an aspect of the invention is to provide use of a compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof in the manufacture of a medicament for modulating calcium channels, especially N-type calcium channels, in a mammal. Also, an aspect of the invention is to provide a compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, for use in a method of modulating calcium channels, especially N-type calcium channels, in a mammal, wherein said method comprises administering to the mammal an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof. A further aspect of the present invention is to provide a pharmaceutical composition useful for treating or preventing stroke, neuronal damage resulting from head trauma, epilepsy, pain (e.g., acute pain, chronic pain, which includes but is not limited to, neuropathic pain and inflammatory pain, or surgical pain), migraine, a mood disorder, schizophrenia, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia, said pharmaceutical composition containing an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, in a mixture with one or more pharmaceutically acceptable carriers. Also, an aspect of the invention is to provide a method for treating or preventing stroke, neuronal damage resulting from head trauma, epilepsy, pain (e.g., acute pain, chronic pain, which includes but is not limited to, neuropathic pain and inflammatory pain, or surgical pain), migraine, a mood disorder, schizophrenia, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia, wherein said method comprises administering to the mammal an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof. Also, an aspect of the invention is to provide use of a compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof in the manufacture of a medicament for treating or preventing stroke, neuronal damage resulting from head trauma, epilepsy, pain (e.g., acute pain, chronic pain, which includes but is not limited to, neuropathic pain and inflammatory pain, or surgical pain), migraine, a mood disorder, schizophrenia, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia in a mammal. A further aspect of the invention is to provide a compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, for use in a method for treating or preventing stroke, neuronal damage resulting from head trauma, epilepsy, pain (e.g., acute pain, chronic pain, which includes but is not limited to, neuropathic pain and inflammatory pain, or surgical pain), migraine, a mood disorder, schizophrenia, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia, whrein said method comprises administering to the mammal an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof. A further aspect of the present invention is to provide radiolabeled compounds of Formula I and the use of such compounds, or their pharmaceutically acceptable salts or solvates, as radioligands for their binding site on the calcium channel. A further aspect of the invention is to provide a method for screening a candidate compound for the ability to bind to a binding site on a protein using a 3H, 11C or 14C radiolabeled compound of Formula I, or a pharmaceutically acceptable salt or a solvate thereof. This method comprises a) introducing a fixed concentration of the radiolabeled compound to a soluble or membrane-associated protein or fragment thereof to form a mixture; b) titrating the mixture with a candidate compound; and c) determining the binding of the candidate compound to said binding site. Additional embodiments and advantages of the invention will be set forth in part in the description that follows, and will flow from the description, or may be learned by practice of the invention. The embodiments and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. Part DESCRIPTION OF EMBODIMENTS: One aspect of the present invention is based on the use of compounds of Formula I, and the pharmaceutically acceptable salts and solvates thereof, as blockers of Ca2+ channels. In view of this property, compounds of Formula I, the pharmaceutically acceptable salts and solvates thereof, are useful for treating or preventing disorders responsive to the blockade of calcium ion channels. In one aspect, compounds of Formula I, the pharmaceutically acceptable salts and solvates thereof, selectively block N-type calcium ion channels and, thus, are useful for treating or preventing disorders responsive to the selective blockade of N-type calcium ion channels. The present invention provides 1) a compound having Formula I: a pharmaceutically acceptable salt or a solvate thereof, wherein: R1 and R2 are each independently hydrogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkoxycarbonyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, optionally substituted aryloxy, or optionally substituted heterocyclyloxy, or R1 and R2 together with the adjacent nitrogen atom form an optionally substituted ring; R3 and R4 are each independently hydrogen, halogen, optionally substituted alkyl or optionally substituted alkoxy; W is —C(R5)(R6)— or —O—; R5 and R6 are each independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, carboxy, alkoxycarbonyl, carbamoyl or alkylcarbamoyl; Y is —S(O)2— or —C(R7)(R8)—; R7 and R8 are each independently hydrogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, or optionally substituted heterocyclyl, or R7 and R8 together with the adjacent carbon atom form an optionally substituted ring; Z is optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl or optionally substituted heterocyclyl; R is alkyl, hydroxyalkyl, alkoxyalkyl, carboxy, alkoxycarbonyl, carbamoyl or alkylcarbamoyl; m is 0 or 1; n is 1 or 2; and p is 0 to 2, excluding i) compounds wherein Y is —CH2— or —CH(CH3)— and Z is unsubstituted phenyl, and ii) compounds wherein Q is (B) and R2 is N-containing heterocyclyl substituted by fluoronaphtylmethyl; 2) the compound of the above 1), a pharmaceutically acceptable salt or a solvate thereof, wherein Q is (A), W is —C(R5)(R6)—, n is 2 and m is 0; 3) the compound of the above 1), a pharmaceutically acceptable salt or a solvate thereof, wherein Q is (A), W is —O—, n and m are simultaneously 1; 4) the compound of the above 2) or 3), a pharmaceutically acceptable salt or a solvate thereof, wherein Y is —S(O)2—; 5) the compound of the above 1), a pharmaceutically acceptable salt or a solvate thereof, wherein Q is (B), n is 2, m is 0, and W is —C(R5)(R6)—; 6) the compound of the above 5), a pharmaceutically acceptable salt or a solvate thereof, wherein Y is —S(O)2—; 7) the compound of any one of the above 1) to 6), a pharmaceutically acceptable salt or a solvate thereof, wherein Z is optionally substituted aryl; 8) the compound of the above 7), a pharmaceutically acceptable salt or a solvate thereof, wherein Z is optionally substituted phenyl; 9) the compound of any one of the above 1) to 8), a pharmaceutically acceptable salt or a solvate thereof, wherein R1 is hydrogen or optionally substituted alkyl, and R2 is optionally substituted alkyl, optionally substituted aryl or optionally substituted cycloalkyl; 10) the compound of any one of the above 1) to 9), a pharmaceutically acceptable salt or solvate thereof, wherein R3 is hydrogen or optionally substituted alkoxy; 11) a pharmaceutical composition comprising a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof and a pharmaceutically acceptable carrier; 12) the pharmaceutical composition of the above 11), which is used for treating or preventing a disorder responsive to the blockade of calcium channels; 13) the pharmaceutical composition of the above 11), which is used for treating or preventing stroke, neuronal damage resulting from head trauma, epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension or cardiac arrhythmia; 14) the pharmaceutical composition of the above 11), which is used for treating or preventing pain selected from chronic pain, acute pain, and surgical pain; 15) the pharmaceutical composition of the above 11), which is used for modulating calcium channels in a mammal; 16) a method of treating or preventing a disorder responsive to the blockade of calcium channels in a mammal suffering from said disorder, comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof; 17) the method of the above 16), wherein a disorder responsive to the blockade of N-type calcium channels is treated or prevented; 18) a method for treating or preventing stroke, neuronal damage resulting from head trauma, epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension or cardiac arrhythmia in a mammal, comprising administering an effective amount of a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof; 19) the method of the above 18), wherein the method is for treating or preventing pain selected from chronic pain, acute pain, and surgical pain; 20) a method of modulating calcium channels in a mammal, comprising administering to the mammal at least one compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof; 21) the method of the above 20), wherein the N-type calcium channel is modulated; 22) a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof, for use in a method for treating or preventing a disorder responsive to the blockade of calcium ion channels in a mammal; 23) a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof, for use in a method for treating or preventing stroke, neuronal damage resulting from head trauma, epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension or cardiac arrhythmia in a mammal; 24) a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof, for use in a method for treating or preventing pain selected from chronic pain, acute pain, and surgical pain; 25) a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof, for use in a method of modulating calcium channels, in a mammal; 26) use of a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof, for manufacturing a medicament for treating or preventing a disorder responsive to the blockade of calcium ion channels in a mammal; 27) use of a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof, for manufacturing a medicament for treating or preventing stroke, neuronal damage resulting from head trauma, epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension or cardiac arrhythmia in a mammal; 28) use of a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof, for manufacturing a medicament for treating or preventing pain selected from chronic pain, acute pain, and surgical pain; and. 29) use of a compound of any one of the above 1) to 10), a pharmaceutically acceptable salt or a solvate thereof, for manufacturing a medicament for modulating calcium channels, in a mammal. In the present specification, the term “halogen” includes fluorine, chlorine, bromine and iodine. Fluorine or chlorine is preferable. The halogen parts of “haloalkyl”, “haloalkoxy” and “haloacyl” are the same as the above “halogen”. The term “alkyl” includes straight or branched chain alkyl having 1 to 10 carbon atoms, for example, 1 to 6 carbon atoms, or 1 to 3 carbon atoms. For example, included are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, n-decyl and the like. “Optionally substituted alkyl” is optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from the followings: 1) halogen, 2) hydroxy, 3) carboxy, 4) mercapto, 5) cyano, 6) alkoxy optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A and Group C, 7) acyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 8) acyloxy optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 9) alkoxycarbonyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A and Group C, 10) aryloxycarbonyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 11) alkylthio optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A and Group C, 12) alkylsulfonyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from the Group A and Group C, 13) amino optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 14) imino optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 15) carbamoyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group B and Group C, 16) carbamoyloxy optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group B and Group C, 17) thiocarbamoyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group B and Group C, 18) cycloalkyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 19) cycloalkenyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 20) aryl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 21) heterocyclyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B, Group C and oxo, 22) aryloxy optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 23) arylthio optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 24) cycloalkylsulfonyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, 25) arylsulfonyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B and Group C, and 26) heterocyclylsulfonyl optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from Group A, Group B, Group C, and oxo. Group A includes hydroxy, halogen, cyano, alkoxy, haloalkoxy, hydroxyalkoxy, arylalkoxy, acyl, haloacyl, aminoacyl, acyloxy, carboxy, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, and optionally substituted amino, wherein the optional substituents are selected from alkyl, hydroxyalkyl, alkoxyalkyl, acyl, cycloalkyl, aryl and heterocyclyl. Group B includes alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, arylalkyl and heterocyclylalkyl. Group C includes optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, optionally substituted aryloxy and optionally substituted heterocyclyl, wherein the optional substituents are selected from Group A, Group B and oxo. The alkyl parts of “alkoxy”, “alkoxycarbonyl”, “alkylsulfonyl”, “alkylthio”, “haloalkyl”, “hydroxyalkyl”, “aminoalkyl”, “alkylamino”, “alkylaminoalkyl”, “arylalkyl”, “haloalkoxy”, “hydroxyalkoxy”, “alkoxyalkyl”, “arylalkoxy”, “alkylcarbamoyl”, “heterocyclylalkyl”, and “alkylenedioxy” are as defined for “alkyl”. The optional substituents in “optionally substituted alkoxy” and “optionally substituted alkoxycarbonyl” include those defined for “optionally substituted alkyl”. The term “alkenyl” refers to straight or branched chain alkenyl of 2 to 10 carbon atoms, for example, 2 to 8 carbon atoms or 3 to 6 carbon atoms, having at least one double bond at any possible positions. Examples of alkenyl groups are vinyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl and the like. The alkenyl parts of “alkenyloxy” is as defined for “alkenyl” The optional substituents in “optionally substituted alkenyl” and “optionally substituted alkenyloxy” are those defined for “optionally substituted alkyl”. The term “alkynyl” refers to straight or branched chain alkynyl of 2 to 10 carbon atoms, for example, 2 to 8 carbon atoms or 3 to 6 carbon atoms having at least one triple bond at any possible positions. Furthermore, “alkynyl” can have at least one double bond at any possible positions. Examples for alkynyl groups are ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl and the like. Substituents for “optionally substituted alkynyl” are those defined for “optionally substituted alkyl”. The term “acyl” refers to (i) straight or branched chain aliphatic acyl having 1 to 10 carbon atoms, for example, 1 to 6 carbon atoms or 1 to 4 carbon atoms, (ii) cyclic aliphatic acyl having 4 to 9 carbon atoms, for example, 4 to 7 carbon atoms, (iii) aroyl and (iv) heterocyclylcarbonyl. Examples for acyl groups are formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, acryloyl, propioloyl, methacryloyl, crotonoyl, cyclopropylcarbonyl, cyclohexylcarbonyl, cyclooctylcarbonyl, benzoyl, pyridinecarbonyl, pyrimidinecarbonyl, piperidincarbonyl, piperazinocarbonyl, morpholinocarbonyl and the like. The acyl part in “acyloxy”, “haloacyl” and “aminoacyl” is that defined for “acyl”. The optional substituents in “optionally substituted acyl” include those defined for “optionally substituted alkyl”, and (ii) cyclic aliphatic acyl, (iii) aroyl and (iv) heterocyclylcarbonyl can be substituted with alkyl optionally substituted with one or more substituents selected from Group A and Group C. The term “cycloalkyl” refers to a carbocycle having 3 to 8 carbon atoms, and includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. “Optionally substituted cycloalkyl” is optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from 1) alkyl optionally substituted with one or more substituents selected from Group A and Group C, and 2) the same as those defined for “optionally substituted alkyl”. The cycloalkyl part of “cycloalkyloxy” and “cycloalkylsulfonyl” is as defined for “cycloalkyl”. The term “cycloalkenyl” refers to a group having at least one double bond at any possible positions in the above defined “cycloalkyl”. Examples are cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and cyclohexadienyl. The cycloalkenyl part in “cycloalkenyloxy” is as defined for “cycloalkenyl”. The optional substituents in “optionally substituted cycloalkyloxy”, “optionally substituted cycloalkenyl”, and “optionally substituted cycloalkenyloxy” are those defined for “optionally substituted cycloalkyl.” The term “alkylamino” includes mono-alkylamino and di-alkylamino. “Optionally substituted amino” is optionally substituted with one or more substituents which can be the same or different, each substituent being independently selected from 1) alkyl optionally substituted with one or more substituents selected from Group A and Group C, and 2) those defined for “optionally substituted alkyl”. The optional substituents in “Optionally substituted carbamoyl” are those defined for “optionally substituted amino.” The term “aryl” includes phenyl, naphthyl, anthryl, phenanthryl, indenyl and the like. The aryl parts in “aryloxy”, “aryloxycarbonyl”, “arylthio”, “arylsulfonyl”, “arylalkyl”, and “arylalkoxy” are those defined above for “aryl”. The terms “heterocyclyl” or “heterocycle” refer to a heterocyclic group containing at least one heteroatom arbitrarily selected from O, S and N. Examples for heterocyclyl are 5- or 6-membered heteroaryl groups, such as pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, furyl and thienyl; fused heterocyclyl groups having two rings, such as indolyl, isoindolyl, indazolyl, indolizinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazoropyridyl, imidazothiazolyl, pyrazinopyridazinyl, quinazolinyl, quinolyl, isoquinolyl, naphthyridinyl, dihydropyridyl, tetrahydroquinolyl and tetrahydrobenzothienyl; fused heterocyclyl groups having three rings such as carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl and dibenzofuryl; and non-aromatic heterocyclyl such as dioxanyl, thiiranyl, oxiranyl, oxathiolanyl, azetidinyl, thianyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, dihydropyridyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolyl and tetrahydroisothiazolyl. The heterocyclyl parts of “heterocyclylalkyl” and “heterocyclylsulfonyl” are those defined above for “heterocyclyl”. Examples of the optional substituents in “optionally substituted aryl”, “optionally substituted phenyl”, “optionally substituted heterocyclyl”, “optionally substituted aryloxy” and “optionally substituted heterocyclyloxy” are selected from 1) the optional substituents defined above for “optionally substituted alkyl”, 2) alkyl optionally substituted with one or more substituents selected from the Group A and Group C, 3) oxo, and 4) alkylenedioxy. These substituents can be attached to one or more of any possible positions. “N-containing non-aromatic heterocyclyl” in the phrase “N-containing non-aromatic heterocyclyl substituted by fluoronaphtylmethyl” includes The ring in the phrase “R1 and R2 together with the adjacent nitrogen atom form an optionally substituted ring” includes a 3-8 membered saturated heterocycle which is optionally substituted and optionally contains additional one or more O, S and/or N. For example, wherein R9 is halogen, hydroxy, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, carboxy, optionally substituted alkoxycarbonyl, optionally substituted acyl or optionally substituted amino, and q is 0, 1 or 2, and the like. The ring in the phrase “R7 and R8 together with the adjacent carbon atom form an optionally substituted ring” includes a 3-8 membered saturated heterocycle, preferably a 3-6 membered saturated heterocycle which is optionally substituted and optionally contains additional one or more O, S and/or N. For example, —Y—Z is wherein R10 is the same as R9, r is 0, 1, or 2, and the like. When p is 2, each R can be the same or different. The compounds of the present invention encompass at least one double bond and can have an E or Z-stereochemistry at said double bond. In one embodiment, preferable Acrylamide Compounds are the compounds of the following Formula IB: wherein (herein after referred to as R1-3) is selected from the following: In another embodiment, useful compounds of Formula IB include those wherein both of R5 and R6 are hydrogen, and p is 0. In another embodiment, useful compounds of Formula IB include those wherein —Y—Z is selected from the following: In another embodiment, useful compounds of Formula IB include those wherein both of R5 and R6 are hydrogen, p is 0 and the combination of R1-3 and Y—Z(═R1-3, —Y—Z) is as follows: (Compound No. R1-3, —Y—Z)═(R1-3a,YZa), (R1-3a,YZb), (R1-3a,YZc), (R1-3a,YZd), (R1-3a,YZe), (R1-3a,YZf), (R1-3a,YZg), (R1-3a,YZh), (R1-3a,YZi), (R1-3a,YZj), (R1-3a,YZk), (R1-3a,YZl), (R1-3a,YZm), (R1-3a,YZn), (R1-3a,YZo), (R1-3a,YZp), (R1-3a,YZq), (R1-3a,YZr), (R1-3a,YZs), (R1-3a,YZt), (R1-3a,YZu), (R1-3a,YZv), (R1-3a,YZw), (R1-3a,YZx), (R1-3a,YZy), (R1-3a,YZz), (R1-3a,YZaa), (R1-3a,YZab), (R1-3a,YZac), (R1-3a,YZad), (R1-3a,YZae), (R1-3a,YZaf), (R1-3a,YZag), (R1-3a,YZah), (R1-3a,YZai), (R1-3a,YZaj), (R1-3a,YZak), (R1-3a,YZal), (R1-3a,YZam), (R1-3a,YZan), (R1-3a,YZao), (R1-3a,YZap), (R1-3a,YZaq), (R1-3a,YZar), (R1-3a,YZas), (R1-3a,YZat), (R1-3a,YZau), (R1-3b,YZa), (R1-3b,YZb), (R1-3b,YZc), (R1-3b,YZd), (R1-3b,YZe), (R1-3b,YZf), (R1-3b,YZg), (R1-3b,YZh), (R1-3b,YZi), (R1-3b,YZj), (R1-3b,YZk), (R1-3b,YZl), (R1-3b,YZm), (R1-3b,YZn), (R1-3b,YZo), (R1-3b,YZp), (R1-3b,YZq), (R1-3b,YZr), (R1-3b,YZs), (R1-3b,YZt), (R1-3b,YZu), (R1-3b,YZv), (R1-3b,YZw), (R1-3b,YZx), (R1-3b,YZy), (R1-3b,YZz), (R1-3b,YZaa), (R1-3b,YZab), (R1-3b,YZac), (R1-3b,YZad), (R1-3b,YZae), (R1-3b,YZaf), (R1-3b,YZag), (R1-3b,YZah), (R1-3b,YZai), (R1-3b,YZaj), (R1-3b,YZak), (R1-3b,YZal), (R1-3b,YZam), (R1-3b,YZan), (R1-3b,YZao), (R1-3b,YZap), (R1-3b,YZaq), (R1-3b,YZar), (R1-3b,YZas), (R1-3b,YZat), (R1-3b,YZau), (R1-3c,YZa), (R1-3c,YZb), (R1-3c,YZc), (R1-3c,YZd), (R1-3c,YZe), (R1-3c,YZf), (R1-3c,YZg), (R1-3c,YZh), (R1-3c,YZi), (R1-3c,YZj), (R1-3c,YZk), (R1-3c,YZl), (R1-3c,YZm), (R1-3c,YZn), (R1-3c,YZo), (R1-3c,YZp), (R1-3c,YZq), (R1-3c,YZr), (R1-3c,YZs), (R1-3c,YZt), (R1-3c,YZu), (R1-3c,YZv), (R1-3c,YZw), (R1-3c,YZx), (R1-3c,YZy), (R1-3c,YZz), (R1-3c,YZaa), (R1-3c,YZab), (R1-3c,YZac), (R1-3c,YZad), (R1-3c,YZae), (R1-3c,YZaf), (R1-3c,YZag), (R1-3c,YZah), (R1-3c,YZai), (R1-3c,YZaj), (R1-3c,YZak), (R1-3c,YZal), (R1-3c,YZam), (R1-3c,YZan), (R1-3c,YZao), (R1-3c,YZap), (R1-3c,YZaq), (R1-3c,YZar), (R1-3c,YZas), (R1-3c,YZat), (R1-3c,YZau), (R1-3d,YZa), (R1-3d,YZb), (R1-3d,YZc), (R1-3d,YZd), (R1-3d,YZe), (R1-3d,YZf), (R1-3d,YZg), (R1-3d,YZh), (R1-3d,YZi), (R1-3d,YZj), (R1-3d,YZk), (R1-3d,YZl), (R1-3d,YZm), (R1-3d,YZn), (R1-3d,YZo), (R1-3d,YZp), (R1-3d,YZq), (R1-3d,YZr), (R1-3d,YZs), (R1-3d,YZt), (R1-3d,YZu), (R1-3d,YZv), (R1-3d,YZw), (R1-3d,YZx), (R1-3d,YZy), (R1-3d,YZz), (R1-3d,YZaa), (R1-3d,YZab), (R1-3d,YZac), (R1-3d,YZad), (R1-3d,YZae), (R1-3d,YZaf), (R1-3d,YZag), (R1-3d,YZah), (R1-3d,YZai), (R1-3d,YZaj), (R1-3d,YZak), (R1-3d,YZal), (R1-3d,YZam), (R1-3d,YZan), (R1-3d,YZao), (R1-3d,YZap), (R1-3d,YZaq), (R1-3d,YZar), (R1-3d,YZas), (R1-3d,YZat), (R1-3d,YZau), (R1-3e,YZa), (R1-3e,YZb), (R1-3e,YZc), (R1-3e,YZd), (R1-3e,YZe), (R1-3e,YZf), (R1-3e,YZg), (R1-3e,YZh), (R1-3e,YZi), (R1-3e,YZj), (R1-3e,YZk), (R1-3e,YZl), (R1-3e,YZm), (R1-3e,YZn), (R1-3e,YZo), (R1-3e,YZp), (R1-3e,YZq), (R1-3e,YZr), (R1-3e,YZs), (R1-3e,YZt), (R1-3e,YZu), (R1-3e,YZv), (R1-3e,YZw), (R1-3e,YZx), (R1-3e,YZy), (R1-3e,YZz), (R1-3e,YZaa), (R1-3e,YZab), (R1-3e,YZac), (R1-3e,YZad), (R1-3e,YZae), (R1-3e,YZaf), (R1-3e,YZag), (R1-3e,YZah), (R1-3e,YZai), (R1-3e,YZaj), (R1-3e,YZak), (R1-3e,YZal), (R1-3e,YZam), (R1-3e,YZan), (R1-3e,YZao), (R1-3e,YZap), (R1-3e,YZaq), (R1-3e,YZar), (R1-3e,YZas), (R1-3e,YZat), (R1-3e,YZau), (R1-3f,YZa), (R1-3f,YZb), (R1-3f,YZc), (R1-3f,YZd), (R1-3f,YZe), (R1-3f,YZf), (R1-3f,YZg), (R1-3f,YZh), (R1-3f,YZi), (R1-3f,YZj), (R1-3f,YZk), (R1-3f,YZl), (R1-3f,YZm), (R1-3f,YZn), (R1-3f,YZo), (R1-3f,YZp), (R1-3f,YZq), (R1-3f,YZr), (R1-3f,YZs), (R1-3f,YZt), (R1-3f,YZu), (R1-3f,YZv), (R1-3f,YZw), (R1-3f,Ya), (R1-3f,YZy), (R1-3f,YZz), (R1-3f,YZaa), (R1-3f,YZab), (R1-3f,YZac), (R1-3f,YZad), (R1-3f,YZae), (R1-3f,YZaf), (R1-3f,YZag), (R1-3f,YZah), (R1-3f,YZai), (R1-3f,YZaj), (R1-3f,YZak), (R1-3f,YZal), (R1-3f,YZam), (R1-3f,YZan), (R1-3f,YZao), (R1-3f,YZap), (R1-3f,YZaq), (R1-3f,YZar), (R1-3f,YZas), (R1-3f,YZat), (R1-3f,YZau), (R1-3g,YZa), (R1-3g,YZb), (R1-3g,YZc), (R1-3g,YZd), (R1-3g,YZe), (R1-3g,YZf), (R1-3g,YZg), (R1-3g,YZh), (R1-3g,YZi), (R1-3g,YZj), (R1-3g,Ya), (R1-3g,YZl), (R1-3g,YZm), (R1-3g,YZn), (R1-3g,YZo), (R1-3g,YZp), (R1-3g,YZq), (R1-3g,YZr), (R1-3g,YZs), (R1-3g,YZt), (R1-3g,YZu), (R1-3g,YZv), (R1-3g,YZw), (R1-3g,YZx), (R1-3g,YZy), (R1-3g,YZz), (R1-3g,YZaa), (R1-3g,YZab), (R1-3g,YZac), (R1-3g,YZad), (R1-3g,YZae), (R1-3g,YZaf), (R1-3g,YZag), (R1-3g,YZah), (R1-3g,YZai), (R1-3g,YZaj), (R1-3g,YZak), (R1-3g,YZal), (R1-3g,YZam), (R1-3g,YZan), (R1-3g,YZao), (R1-3g,YZap), (R1-3g,YZaq), (R1-3g,YZar), (R1-3g,YZas), (R1-3g,YZat), (R1-3g,YZau), (R1-3h,YZa), (R1-3h,YZb), (R1-3h,YZc), (R1-3h,YZd), (R1-3h,YZe), (R1-3h,YZf), (R1-3h,YZg), (R1-3h,YZh), (R1-3h,YZi), (R1-3h,YZj), (R1-3h,YZk), (R1-3h,YZl), (R1-3h,YZm), (R1-3h,YZn), (R1-3h,YZo), (R1-3h,YZp), (R1-3h,YZq), (R1-3h,YZr), (R1-3h,YZs), (R1-3h,YZt), (R1-3h,YZu), (R1-3h,YZv), (R1-3h,YZw), (R1-3h,YZx), (R1-3h,YZy), (R1-3h,YZz), (R1-3h,YZaa), (R1-3h,YZab), (R1-3h,YZac), (R1-3h,YZad), (R1-3h,YZae), (R1-3h,YZaf), (R1-3h,YZag), (R1-3h,YZah), (R1-3h,YZai), (R1-3h,YZaj), (R1-3h,YZak), (R1-3h,YZal), (R1-3h,YZam), (R1-3h,YZan), (R1-3h,YZao), (R1-3h,YZap), (R1-3h,YZaq), (R1-3h,YZar), (R1-3h,YZas), (R1-3h,YZat), (R1-3h,YZau), (R1-3i,YZa), (R1-3i,YZb), (R1-3i,YZc), (R1-3i,YZd), (R1-3i,YZe), (R1-3i,YZf), (R1-3i,YZg), (R1-3i,YZh), (R1-3i,YZi), (R1-3i,YZj), (R1-3i,Ya), (R1-3i,YZl), (R1-3i,YZm), (R1-3i,YZn), (R1-3i,YZo), (R1-3i,YZp), (R1-3i,YZq), (R1-3i,YZr), (R1-3i,YZs), (R1-3i,YZt), (R1-3i,YZu), (R1-3i,YZv), (R1-3i,YZw), (R1-3i,YZx), (R1-3i,YZy), (R1-3i,YZz), (R1-31,YZaa), (R1-3i,YZab), (R1-3i,YZac), (R1-3i,YZad), (R1-3i,YZae), (R1-3i,YZaf), (R1-3i,YZag), (R1-3i,YZah), (R1-3i,YZai), (R1-3i,YZaj), (R1-3i,YZak), (R1-3i,YZal), (R1-3i,YZam), (R1-3i,YZan), (R1-3i,YZao), (R1-3i,YZap), (R1-3i,YZaq), (R1-3i,YZar), (R1-3i,YZas), (R1-3i,YZat), (R1-3i,YZau), (R1-3j,YZa), (R1-3j,YZb), (R1-3j,YZc), (R1-3j,YZd), (R1-3j,YZe), (R1-3j,YZf), (R1-3j,YZg), (R1-3j,YZh), (R1-3j,YZi), (R1-3j,YZj), (R1-3j,YZk), (R1-3j,YZl), (R1-3j,YZm), (R1-3j,YZn), (R1-3j,YZo), (R1-3j,YZp), (R1-3j,YZq), (R1-3j,YZr), (R1-3j,YZs), (R1-3j,YZt), (R1-3j,YZu), (R1-3j,YZv), (R1-3j,YZw), (R1-3j,YZx), (R1-3j,YZy), (R1-3j,YZz), (R1-3j,YZaa), (R1-3j,YZab), (R1-3j,YZac), (R1-3j,YZad), (R1-3j,YZae), (R1-3j,YZaf), (R1-3j,YZag), (R1-3j,YZah), (R1-3j,YZai), (R1-3j,YZaj), (R1-3j,YZak), (R1-3j,YZal), (R1-3j,YZam), (R1-3j,YZan), (R1-3j,YZao), (R1-3j,YZap), (R1-3j,YZaq), (R1-3j,YZar), (R1-3j,YZas), (R1-3j,YZat), (R1-3j,YZau), (R1-3k,YZa), (R1-3k,YZb), (R1-3k,YZc), (R1-3k,YZd), (R1-3k,YZe), (R1-3k,YZf), (R1-3k,YZg), (R1-3k,YZh), (R1-3k,YZi), (R1-3k,YZj), (R1-3k,YZk), (R1-3k,YZl), (R1-3k,YZm), (R1-3k,YZn), (R1-3k,YZo), (R1-3k,YZp), (R1-3k,YZq), (R1-3k,YZr), (R1-3k,YZs), (R1-3k,YZt), (R1-3k,YZu), (R1-3k,YZv), (R1-3k,YZw), (R1-3k,YZx), (R1-3k,YZy), (R1-3k,YZz), (R1-3k,YZaa), (R1-3k,YZab), (R1-3k,YZac), (R1-3k,YZad), (R1-3k,YZae), (R1-3k,YZaf), (R1-3k,YZag), (R1-3k,YZah), (R1-3k,YZai), (R1-3k,YZaj), (R1-3k,YZak), (R1-3k,YZal), (R1-3k,YZam), (R1-3k,YZan), (R1-3k,YZao), (R1-3k,YZap), (R1-3k,YZaq), (R1-3k,YZar), (R1-3k,YZas), (R1-3k,YZat), (R1-3k,YZau), (R1-3l,YZa), (R1-3l,YZb), (R1-3l,YZc), (R1-3l,YZd), (R1-3l,YZe), (R1-3l,YZf, (R1-3l,YZg), (R1-31,YZh), (R1-3l,YZi), (R1-3l,YZj), (R1-3l,YZk), (R1-3l,YZl), (R1-3l,YZm), (R1-31,YZn), (R1-3l,YZo), (R1-3l,YZp), (R1-3l,YZq), (R1-3l,YZr), (R1-3l,YZs), (R1-3l,YZt), (R1-3l,YZu), (R1-3l,YZv), (R1-3l,YZw), (R1-3l,YZx), (R1-3l,YZy), (R1-3l,YZz), (R1-3l,YZaa), (R1-3l,YZab), (R1-3l,YZac), (R1-3l,YZad), (R1-3l,YZae), (R1-3l,YZaf), (R1-3l,YZag), (R1-3l,YZah), (R1-3l,YZai), (R1-3l,YZaj), (R1-3l,YZak), (R1-3l,YZal), (R1-3l,YZam), (R1-3l,YZan), (R1-3l,YZao), (R1-3l,YZap), (R1-31,YZaq), (R1-3l,YZar), (R1-3l,YZas), (R1-3l,YZat), (R1-3l,YZau), (R1-3m,YZa), (R1-3m,YZb), (R1-3m,YZc), (R1-3m,YZd), (R1-3m,YZe), (R1-3m,YZf), (R1-3m,YZg), (R1-3m,YZh), (R1-3m,YZi), (R1-3m,YZj), (R1-3m,YZk), (R1-3m,YZl), (R1-3m,YZm), (R1-3m,YZn), (R1-3m,YZo), (R1-3m,YZp), (R1-3m,YZq), (R1-3m,YZr), (R1-3m,YZs), (R1-3m,YZt), (R1-3m,YZu), (R1-3 m,YZv), (R1-3m,YZw), (R1-3m,YZx), (R1-3m,YZy), (R1-3m,YZz), (R1-3m,YZaa), (R1-3m,YZab), (R1-3m,YZac), (R1-3m,YZad), (R1-3m,YZae), (R1-3m,YZat), (R1-3m,YZag), (R1-3m,YZah), (R1-3m,YZai), (R1-3m,YZaj), (R1-3m,YZak), (R1-3m,YZal), (R1-3m,YZam), (R1-3m,YZan), (R1-3m,YZao), (R1-3m,YZap), (R1-3m,YZaq), (R1-3m,YZar), (R1-3m,YZas), (R1-3m,YZat), (R1-3m,YZau), (R1-3n,YZa), (R1-3n,YZb), (R1-3n,YZc), (R1-3n,YZd), (R1-3n,YZe), (R1-3n,YZf), (R1-3n,YZg), (R1-3n,YZh), (R1-3n,YZi), (R1-3n,YZj), (R1-3n,YZk), (R1-3n,YZl), (R1-3n,YZm), (R1-3n,YZn), (R1-3n,YZo), (R1-3n,YZp), (R1-3n,YZq), (R1-3n,YZr), (R1-3n,YZs), (R1-3n,YZt), (R1-3n,YZu), (R1-3n,YZv), (R1-3n,YZw), (R1-3n,YZx), (R1-3n,YZy), (R1-3n,YZz), (R1-3n,YZaa), (R1-3n,YZab), (R1-3n,YZac), (R1-3n,YZad), (R1-3n,YZae), (R1-3n,YZaf), (R1-3n,YZag), (R1-3n,YZah), (R1-3n,YZai), (R1-3n,YZaj), (R1-3n,YZak), (R1-3n,YZal), (R1-3n,YZam), (R1-3n,YZan), (R1-3n,YZao), (R1-3n,YZap), (R1-3n,YZaq), (R1-3n,YZar), (R1-3n,YZas), (R1-3n,YZat), (R1-3n,YZau), (R1-3o,YZa), (R1-3o,YZb), (R1-3o,YZc), (R1-3o,YZd), (R1-3o,YZe), (R1-3o,YZf), (R1-3o,YZg), (R1-3o,YZh), (R1-3o,YZi), (R1-3o,YZj), (R1-3o,YZk), (R1-3o,YZl), (R1-3o,YZm), (R1-3o,YZn), (R1-3o,YZo), (R1-3o,YZp), (R1-3o,YZq), (R1-3o,YZr), (R1-3o,YZs), (R1-3o,YZt), (R1-3o,YZu), (R1-3o,YZv), (R1-3o,YZw), (R1-3o,YZx), (R1-3o,YZy), (R1-3o,YZz), (R1-3o,YZaa), (R1-3o,YZab), (R1-3o,YZac), (R1-3o,YZad), (R1-3o,YZae), (R1-3o,YZaf), (R1-3o,YZag), (R1-3o,YZah), (R1-3o,YZai), (R1-3o,YZaj), (R1-3o,YZak), (R1-3o,YZal), (R1-3o,YZam), (R1-3o,YZan), (R1-3o,YZao), (R1-3o,YZap), (R1-3o,YZaq), (R1-3o,YZar), (R1-3o,YZas), (R1-3o,YZat), (R1-3o,YZau), (R1-3p,YZa), (R1-3p,YZb), (R1-3p,YZc), (R1-3p,YZd), (R1-3p,YZe), (R1-3p,YZf), (R1-3p,YZg), (R1-3p,YZh), (R1-3p,YZi), (R1-3p,YZj), (R1-3p,YZk), (R1-3p,YZl), (R1-3p,YZm), (R1-3p,YZn), (R1-3p,YZo), (R1-3p,YZp), (R1-3p,YZq), (R1-3p,YZr), (R1-3p,YZs), (R1-3p,YZt), (R1-3p,YZu), (R1-3p,YZv), (R1-3p,YZw), (R1-3p,YZx), (R1-3p,YZy), (R1-3p,YZz), (R1-3p,YZaa), (R1-3p,YZab), (R1-3p,YZac), (R1-3p,YZad), (R1-3p,YZae), (R1-3p,YZaf), (R1-3p,YZag), (R1-3p,YZah), (R1-3p,YZai), (R1-3p,YZaj), (R1-3p,YZak), (R1-3p,YZal), (R1-3p,YZam), (R1-3p,YZan), (R1-3p,YZao), (R1-3p,YZap), (R1-3p,YZaq), (R1-3p,YZar), (R1-3p,YZas), (R1-3p,YZat), (R1-3p,YZau), (R1-3q,YZa), (R1-3q,YZb), (R1-3q,YZc), (R1-3q,YZd), (R1-3q,YZe), (R1-3q,YZf), (R1-3q,YZg), (R1-3q,YZh), (R1-3q,YZi), (R1-3q,YZj), (R1-3q,YZk), (R1-3q,YZl), (R1-3q,YZm), (R1-3q,YZn), (R1-3q,YZo), (R1-3q,YZp), (R1-3q,YZq), (R1-3q,YZr), (R1-3q,YZs), (R1-3q,YZt), (R1-3q,YZu), (R1-3q,YZv), (R1-3q,YZw), (R1-3q,YZx), (R1-3q,YZy), (R1-3q,YZz), (R1-3q,YZaa), (R1-3q,YZab), (R1-3q,YZac), (R1-3q,YZad), (R1-3q,YZae), (R1-3q,YZaf), (R1-3q,YZag), (R1-3q,YZah), (R1-3q,YZai), (R1-3q,YZaj), (R1-3q,YZak), (R1-3q,YZal), (R1-3q,YZam), (R1-3q,YZan), (R1-3q,YZao), (R1-3q,YZap), (R1-3q,YZaq), (R1-3q,YZar), (R1-3q,YZas), (R1-3q,YZat), (R1-3q,YZau), (R1-3r,YZa), (R1-3r,YZb), (R1-3r,YZc), (R1-3r,YZd), (R1-3r,YZe), (R1-3r,YZf), (R1-3r,YZg), (R1-3r,YZh), (R1-3r,YZi), (R1-3r,YZj), (R1-3r,YZk), (R1-3r,YZl), (R1-3r,YZm), (R1-3r,YZn), (R1-3r,YZo), (R1-3r,YZp), (R1-3r,YZq), (R1-3r,YZr), (R1-3r,YZs), (R1-3r,YZt), (R1-3r,YZu), (R1-3r,YZv), (R1-3r,YZw), (R1-3r,YZx), (R1-3r,YZy), (R1-3r,YZz), (R1-3r,YZaa), (R1-3r,YZab), (R1-3r,YZac), (R1-3r,YZad), (R1-3r,YZae), (R1-3r,YZaf), (R1-3r,YZag), (R1-3r,YZah), (R1-3r,YZai), (R1-3r,YZaj), (R1-3r,YZak), (R1-3r,YZal), (R1-3r,YZam), (R1-3r,YZan), (R1-3r,YZao), (R1-3r,YZap), (R1-3r,YZaq), (R1-3r,YZar), (R1-3r,YZas), (R1-3r,YZat), (R1-3r,YZau), (R1-3s,YZa), (R1-3s,YZb), (R1-3s,YZc), (R1-3s,YZd), (R1-3s,YZe), (R1-3s,YZf), (R1-3s,YZg), (R1-3s,YZh), (R1-3s,YZi), (R1-3s,YZj), (R1-3s,YZk), (R1-3s,YZl), (R1-3s,YZm), (R1-3s,YZn), (R1-3s,YZo), (R1-3s,YZp), (R1-3s,YZq), (R1-3s,YZr), (R1-3s,YZs), (R1-3s,YZt), (R1-3s,YZu), (R1-3s,YZv), (R1-3s,YZw), (R1-3s,YZx), (R1-3s,YZy), (R1-3s,YZz), (R1-3s,YZaa), (R1-3s,YZab), (R1-3s,YZac), (R1-3s,YZad), (R1-3s,YZae), (R1-3s,YZaf), (R1-3s,YZag), (R1-3s,YZah), (R1-3s,YZai), (R1-3s,YZaj), (R1-3s,YZak), (R1-3s,YZal), (R1-3s,YZam), (R1-3s,YZan), (R1-3s,YZao), (R1-3s,YZap), (R1-3s,YZaq), (R1-3s,YZar), (R1-3s,YZas), (R1-3s,YZat), (R1-3s,YZau), (R1-3t,YZa), (R1-3t,YZb), (R1-3t,YZc), (R1-3t,YZd), (R1-3t,YZe), (R1-3t,YZf), (R1-3t,YZg), (R1-3t,YZh), (R1-3t,YZi), (R1-3t,YZj), (R1-3t,YZk), (R1-3t,YZl), (R1-3t,YZm), (R1-3t,YZn), (R1-3t,YZo), (R1-3t,YZp), (R1-3t,YZq), (R1-3t,YZr), (R1-3t,YZs), (R1-3t,YZt), (R1-3t,YZu), (R1-3t,YZv), (R1-3t,YZw), (R1-3t,YZx), (R1-3t,YZy), (R1-3t,YZz), (R1-3t,YZaa), (R1-3t,YZab), (R1-3t,YZac), (R1-3t,YZad), (R1-3t,YZae), (R1-3t,YZaf), (R1-3t,YZag), (R1-3t,YZah), (R1-3t,YZai), (R1-3t,YZaj), (R1-3t,YZak), (R1-3t,YZal), (R1-3t,YZam), (R1-3t,YZan), (R1-3t,YZao), (R1-3t,YZap), (R1-3t,YZaq), (R1-3t,YZar), (R1-3t,YZas), (R1-3t,YZat), (R1-3t,YZau), (R1-3u,YZa), (R1-3u,YZb), (R1-3u,YZc), (R1-3u,YZd), (R1-3u,YZe), (R1-3u,YZf), (R1-3u,YZg), (R1-3u,YZh), (R1-3u,YZi), (R1-3u,YZj), (R1-3u,YZk), (R1-3u,YZl), (R1-3u,YZm), (R1-3u,YZn), (R1-3u,YZo), (R1-3u,YZp), (R1-3u,YZq), (R1-3u,YZr), (R1-3u,YZs), (R1-3u,YZt), (R1-3u,YZu), (R1-3u,YZv), (R1-3u,YZw), (R1-3u,YZx), (R1-3u,YZy), (R1-3u,YZz), (R1-3u,YZaa), (R1-3u,YZab), (R1-3u,YZac), (R1-3u,YZad), (R1-3u,YZae), (R1-3u,YZaf), (R1-3u,YZag), (R1-3u,YZah), (R1-3u,YZai), (R1-3u,YZaj), (R1-3u,YZak), (R1-3u,YZal), (R1-3u,YZam), (R1-3u,YZan), (R1-3u,YZao), (R1-3u,YZap), (R1-3u,YZaq), (R1-3u,YZar), (R1-3u,YZas), (R1-3u,YZat), (R1-3u,YZau), (R1-3v,YZa), (R1-3v,YZb), (R1-3v,YZc), (R1-3v,YZd), (R1-3v,YZe), (R1-3v,YZf), (R1-3v,YZg), (R1-3v,YZh), (R1-3v,YZi), (R1-3v,YZj), (R1-3v,YZk), (R1-3v,YZl), (R1-3v,YZm), (R1-3v,YZn), (R1-3v,YZo), (R1-3v,YZp), (R1-3v,YZq), (R1-3v,YZr), (R1-3v,YZs), (R1-3v,YZt), (R1-3v,YZu), (R1-3v,YZv), (R1-3v,YZw), (R1-3v,YZx), (R1-3v,YZy), (R1-3v,YZz), (R1-3v,YZaa), (R1-3v,YZab), (R1-3v,YZac), (R1-3v,YZad), (R1-3v,YZae), (R1-3v,YZaf), (R1-3v,YZag), (R1-3v,YZah), (R1-3v,YZai), (R1-3v,YZaj), (R1-3v,YZak), (R1-3v,YZal), (R1-3v,YZam), (R1-3v,YZan), (R1-3v,YZao), (R1-3v,YZap), (R1-3v,YZaq), (R1-3v,YZar), (R1-3v,YZas), (R1-3v,YZat), (R1-3v,YZau), (R1-3w,YZa), (R1-3w,YZb), (R1-3w,YZc), (R1-3w,YZd), (R1-3w,YZe), (R1-3w,YZf), (R1-3w,YZg), (R1-3w,YZh), (R1-3w,YZi), (R1-3w,YZj), (R1-3w,YZk), (R1-3w,YZl), (R1-3w,YZm), (R1-3w,YZn), (R1-3w,YZo), (R1-3w,YZp), (R1-3w,YZq), (R1-3w,YZr), (R1-3w,YZs), (R1-3w,YZt), (R1-3w,YZu), (R1-3w,YZv), (R1-3w,YZw), (R1-3w,YZx), (R1-3w,YZy), (R1-3w,YZz), (R1-3w,YZaa), (R1-3w,YZab), (R1-3w,YZac), (R1-3w,YZad), (R1-3w,YZae), (R1-3w,YZaf), (R1-3w,YZag), (R1-3w,YZah), (R1-3w,YZai), (R1-3w,YZaj), (R1-3w,YZak), (R1-3w,YZal), (R1-3w,YZam), (R1-3w,YZan), (R1-3w,YZao), (R1-3w,YZap), (R1-3w,YZaq), (R1-3w,YZar), (R1-3w,YZas), (R1-3w,YZat), (R1-3w,YZau), (R1-3x,YZa), (R1-3x,YZb), (R1-3x,YZc), (R1-3x,YZd), (R1-3x,YZe), (R1-3x,YZf), (R1-3x,YZg), (R1-3x,Ya), (R1-3x,YZi), (R1-3x,YZj), (R1-3x,YZk), (R1-3x,YZl), (R1-3x,YZm), (R1-3x,YZn), (R1-3x,YZo), (R1-3x,YZp), (R1-3x,YZq), (R1-3x,YZr), (R1-3x,YZs), (R1-3x,YZt), (R1-3x,YZu), (R1-3x,YZv), (R1-3x,YZw), (R1-3x,YZx), (R1-3x,YZy), (R1-3x,YZz), (R1-3x,YZaa), (R1-3x,YZab), (R1-3x,YZac), (R1-3x,YZad), (R1-3x,YZae), (R1-3x,YZaf), (R1-3x,YZag), (R1-3x,YZah), (R1-3x,YZai), (R1-3x,YZaj), (R1-3x,YZak), (R1-3x,YZal), (R1-3x,YZam), (R1-3x,YZan), (R1-3x,YZao), (R1-3x,YZap), (R1-3x,YZaq), (R1-3x,YZar), (R1-3x,YZas), (R1-3x,YZat), (R1-3x,YZau), (R1-3y,YZa), (R1-3y,YZb), (R1-3y,YZc), (R1-3y,YZd), (R1-3y,YZe), (R1-3y,YZf), (R1-3y,YZg), (R1-3y,YZh), (R1-3y,YZi), (R1-3y,YZj), (R1-3y,YZk), (R1-3y,YZl), (R1-3y,YZm), (R1-3y,YZn), (R1-3y,YZo), (R1-3y,YZp), (R1-3y,YZq), (R1-3y,YZr), (R1-3y,YZs), (R1-3y,YZt), (R1-3y,YZu), (R1-3y,YZv), (R1-3y,YZw), (R1-3y,YZx), (R1-3y,YZy), (R1-3y,YZz), (R1-3y,YZaa), (R1-3y,YZab), (R1-3y,YZac), (R1-3y,YZad), (R1-3y,YZae), (R1-3y,YZaf), (R1-3y,YZag), (R1-3y,YZah), (R1-3y,YZai), (R1-3y,YZaj), (R1-3y,YZak), (R1-3y,YZal), (R1-3y,YZam), (R1-3y,YZan), (R1-3y,YZao), (R1-3y,YZap), (R1-3y,YZaq), (R1-3y,YZar), (R1-3y,YZas), (R1-3y,YZat), (R1-3y,YZau), (R1-3z,YZa), (R1-3z,YZb), (R1-3z,YZc), (R1-3z,YZd), (R1-3z,YZe), (R1-3z,YZf), (R1-3z,YZg), (R1-3z,YZh), (R1-3z,YZi), (R1-3z,YZj), (R1-3z,YZk), (R1-3z,YZl), (R1-3z,YZm), (R1-3z,YZn), (R1-3z,YZo), (R1-3z,YZp), (R1-3z,YZq), (R1-3z,YZr), (R1-3z,YZs), (R1-3z,YZt), (R1-3z,YZu), (R1-3z,YZv), (R1-3z,YZw), (R1-3z,YZx), (R1-3z,YZy), (R1-3z,YZz), (R1-3z,YZaa), (R1-3z,YZab), (R1-3z,YZac), (R1-3z,YZad), (R1-3z,YZae), (R1-3z,YZaf), (R1-3z,YZag), (R1-3z,YZah), (R1-3z,YZai), (R1-3z,YZaj), (R1-3z,YZak), (R1-3z,YZal), (R1-3z,YZam), (R1-3z,YZan), (R1-3z,YZao), (R1-3z,YZap), (R1-3z,YZaq), (R1-3z,YZar), (R1-3z,YZas), (R1-3z,YZat), (R1-3z,YZau), (R1-3aa,YZa), (R1-3aa,YZb), (R1-3aa,YZc), (R1-3aa,YZd), (R1-3aa,YZe), (R1-3aa,YZf), (R1-3aa,YZg), (R1-3aa,YZh), (R1-3aa,YZi), (R1-3aa,YZj), (R1-3aa,YZk), (R1-3aa,YZl), (R1-3aa,YZm), (R1-3aa,YZn), (R1-3aa,YZo), (R1-3aa,YZp), (R1-3aa,YZq), (R1-3aa,YZr), (R1-3aa,YZs), (R1-3aa,YZt), (R1-3aa,YZu), (R1-3aa,YZv), (R1-3aa,YZw), (R1-3aa,YZx), (R1-3aa,YZy), (R1-3aa,YZz), (R1-3aa,YZaa), (R1-3aa,YZab), (R1-3aa,YZac), (R1-3aa,YZad), (R1-3aa,YZae), (R1-3aa,YZaf), (R1-3aa,YZag), (R1-3aa,YZah), (R1-3aa,YZai), (R1-3aa,YZaj), (R1-3aa,YZak), (R1-3aa,YZal), (R1-3aa,YZam), (R1-3aa,YZan), (R1-3aa,YZao), (R1-3aa,YZap), (R1-3aa,YZaq), (R1-3aa,YZar), (R1-3aa,YZas), (R1-3aa,YZat), (R1-3aa,YZau), (R1-3ab,YZa), (R1-3ab,YZb), (R1-3ab,YZc), (R1-3ab,YZd), (R1-3ab,YZe), (R1-3ab,YZf), (R1-3ab,YZg), (R1-3ab,YZh), (R1-3ab,YZi), (R1-3ab,YZj), (R1-3ab,YZk), (R1-3ab,YZl), (R1-3ab,YZm), (R1-3ab,YZn), (R1-3ab,YZo), (R1-3ab,YZp), (R1-3ab,YZq), (R1-3ab,YZr), (R1-3ab,YZs), (R1-3ab,YZt), (R1-3ab,YZu), (R1-3ab,YZv), (R1-3ab,YZw), (R1-3ab,YZx), (R1-3ab,YZy), (R1-3ab,YZz), (R1-3ab,YZaa), (R1-3ab,YZab), (R1-3ab,YZac), (R1-3ab,YZad), (R1-3ab,YZae), (R1-3ab,YZaf), (R1-3ab,YZag), (R1-3ab,YZah), (R1-3ab,YZai), (R1-3ab,YZaj), (R1-3ab,YZak), (R1-3ab,YZal), (R1-3ab,YZam), (R1-3ab,YZan), (R1-3ab,YZao), (R1-3ab,YZap), (R1-3ab,YZaq), (R1-3ab,YZar), (R1-3ab,YZas), (R1-3ab,YZat), (R1-3ab,YZau), (R1-3ac,YZa), (R1-3ac,YZb), (R1-3ac,YZc), (R1-3ac,YZd), (R1-3ac,YZe), (R1-3ac,YZf), (R1-3ac,YZg), (R1-3ac,YZh), (R1-3ac,YZi), (R1-3ac,YZj), (R1-3ac,YZk), (R1-3ac,YZl), (R1-3ac,YZm), (R1-3ac,YZn), (R1-3ac,YZo), (R1-3ac,YZp), (R1-3ac,YZq), (R1-3ac,YZr), (R1-3ac,YZs), (R1-3ac,YZt), (R1-3ac,YZu), (R1-3ac,YZv), (R1-3ac,YZw), (R1-3ac,YZx), (R1-3ac,YZy), (R1-3ac,YZz), (R1-3ac,YZaa), (R1-3ac,YZab), (R1-3ac,YZac), (R1-3ac,YZad), (R1-3ac,YZae), (R1-3ac,YZaf), (R1-3ac,YZag), (R1-3ac,YZah), (R1-3ac,YZai), (R1-3ac,YZaj), (R1-3ac,YZak), (R1-3ac,YZal), (R1-3ac,YZam), (R1-3ac,YZan), (R1-3ac,YZao), (R1-3ac,YZap), (R1-3ac,YZaq), (R1-3ac,YZar), (R1-3ac,YZas), (R1-3ac,YZat), (R1-3ac,YZau), (R1-3ad,YZa), (R1-3ad,YZb), (R1-3ad,YZc), (R1-3ad,YZd), (R1-3ad,YZe), (R1-3ad,YZf), (R1-3ad,YZg), (R1-3ad,Ya), (R1-3ad,YZi), (R1-3ad,YZj), (R1-3ad,YZk), (R1-3ad,YZl), (R1-3ad,YZm), (R1-3ad,YZn), (R1-3ad,YZo), (R1-3ad,YZp), (R1-3ad,YZq), (R1-3ad,YZr), (R1-3ad,YZs), (R1-3ad,YZt), (R1-3ad,YZu), (R1-3ad,YZv), (R1-3ad,YZw), (R1-3ad,Ya), (R1-3ad,YZy), (R1-3ad,YZz), (R1-3ad,YZaa), (R1-3ad,YZab), (R1-3ad,YZac), (R1-3ad,YZad), (R1-3ad,YZae), (R1-3ad,YZaf), (R1-3ad,YZag), (R1-3ad,YZah), (R1-3ad,YZai), (R1-3ad,YZaj), (R1-3ad,YZak), (R1-3ad,YZal), (R1-3ad,YZam), (R1-3ad,YZan), (R1-3ad,YZao), (R1-3ad,YZap), (R1-3ad,YZaq), (R1-3ad,YZar), (R1-3ad,YZas), (R1-3ad,YZat), (R1-3ad,YZau), (R1-3ae,YZa), (R1-3ae,YZb), (R1-3ae,YZc), (R1-3ae,YZd), (R1-3ae,YZe), (R1-3ae,YZf), (R1-3ae,YZg), (R1-3ae,YZh), (R1-3ae,YZi), (R1-3ae,YZj), (R1-3ae,YZk), (R1-3ae,YZl), (R1-3ae,YZm), (R1-3ae,YZn), (R1-3ae,YZo), (R1-3ae,YZp), (R1-3ae,YZq), (R1-3ae,YZr), (R1-3ae,YZs), (R1-3ae,YZt), (R1-3ae,YZu), (R1-3ae,YZv), (R1-3ae,YZw), (R1-3ae,Ya), (R1-3ae,YZy), (R1-3ae,YZz), (R1-3ae,YZaa), (R1-3ae,YZab), (R1-3ae,YZac), (R1-3ae,YZad), (R1-3ae,YZae), (R1-3ae,YZaf), (R1-3ae,YZag), (R1-3ae,YZah), (R1-3ae,YZai), (R1-3ae,YZaj), (R1-3ae,YZak), (R1-3ae,YZal), (R1-3ae,YZam), (R1-3ae,YZan), (R1-3ae,YZao), (R1-3ae,YZap), (R1-3ae,YZaq), (R1-3ae,YZar), (R1-3ae,YZas), (R1-3ae,YZat), (R1-3ae,YZau), (R1-3af,YZa), (R1-3af,YZb), (R1-3af,YZc), (R1-3af,YZd), (R1-3af,YZe), (R1-3af,YZf), (R1-3af,YZg), (R1-3af,YZh), (R1-3af,YZi), (R1-3af,YZj), (R1-3af,YZk), (R1-3af,YZl), (R1-3af,YZm), (R1-3af,YZn), (R1-3af,YZo), (R1-3af,YZp), (R1-3af,YZq), (R1-3af,YZr), (R1-3af,YZs), (R1-3af,YZt), (R1-3af,YZu), (R1-3af,YZv), (R1-3af,YZw), (R1-3af,YZx), (R1-3af,YZy), (R1-3af,YZz), (R1-3af,YZaa), (R1-3af,YZab), (R1-3af,YZac), (R1-3af,YZad), (R1-3af,YZae), (R1-3af,YZaf), (R1-3af,YZag), (R1-3af,YZah), (R1-3af,YZai), (R1-3af,YZaj), (R1-3af,YZak), (R1-3af,YZal), (R1-3af,YZam), (R1-3af,YZan), (R1-3af,YZao), (R1-3af,YZap), (R1-3af,YZaq), (R1-3af,YZar), (R1-3af,YZas), (R1-3af,YZat), (R1-3af,YZau), (R1-3ag,YZa), (R1-3ag,YZb), (R1-3ag,YZc), (R1-3ag,YZd), (R1-3ag,YZe), (R1-3ag,YZf), (R1-3ag,YZg), (R1-3ag,YZh), (R1-3ag,YZi), (R1-3ag,YZj), (R1-3ag,YZk), (R1-3ag,YZl), (R1-3ag,YZm), (R1-3ag,YZn), (R1-3ag,YZo), (R1-3ag,YZp), (R1-3ag,YZq), (R1-3ag,YZr), (R1-3ag,YZs), (R1-3ag,YZt), (R1-3ag,YZu), (R1-3ag,YZv), (R1-3ag,YZw), (R1-3ag,Ya), (R1-3ag,YZy), (R1-3ag,YZz), (R1-3ag,YZaa), (R1-3ag,YZab), (R1-3ag,YZac), (R1-3ag,YZad), (R1-3ag,YZae), (R1-3ag,YZaf), (R1-3ag,YZag), (R1-3ag,YZah), (R1-3ag,YZai), (R1-3ag,YZaj), (R1-3ag,YZak), (R1-3ag,YZal), (R1-3ag,YZam), (R1-3ag,YZan), (R1-3ag,YZao), (R1-3ag,YZap), (R1-3ag,YZaq), (R1-3ag,YZar), (R1-3ag,YZas), (R1-3ag,YZat), (R1-3ag,YZau), (R1-3ah,YZa), (R1-3ah,YZb), (R1-3ah,YZc), (R1-3ah,YZd), (R1-3ah,YZe), (R1-3ah,YZf), (R1-3ah,YZg), (R1-3ah,YZh), (R1-3ah,YZi), (R1-3ah,YZj), (R1-3ah,YZk), (R1-3ah,YZl), (R1-3ah,YZm), (R1-3ah,YZn), (R1-3ah,YZo), (R1-3ah,YZp), (R1-3ah,YZq), (R1-3ah,YZr), (R1-3ah,YZs), (R1-3ah,YZt), (R1-3ah,YZu), (R1-3ah,YZv), (R1-3ah,YZw), (R1-3ah,YZx), (R1-3ah,YZy), (R1-3ah,YZz), (R1-3ah,YZaa), (R1-3ah,YZab), (R1-3ah,YZac), (R1-3ah,YZad), (R1-3ah,YZae), (R1-3ah,YZaf), (R1-3ah,YZag), (R1-3ah,YZah), (R1-3ah,YZai), (R1-3ah,YZaj), (R1-3ah,YZak), (R1-3ah,YZal), (R1-3ah,YZam), (R1-3ah,YZan), (R1-3ah,YZao), (R1-3ah,YZap), (R1-3ah,YZaq), (R1-3ah,YZar), (R1-3ah,YZas), (R1-3ah,YZat), (R1-3ah,YZau), (R1-3ai,YZa), (R1-3ai,YZb), (R1-3ai,YZc), (R1-3ai,YZd), (R1-3ai,YZe), (R1-3ai,YZf), (R1-3ai,YZg), (R1-3ai,YZh), (R1-3ai,YZi), (R1-3ai,YZj), (R1-3ai,YZk), (R1-3ai,YZl), (R1-3ai,YZm), (R1-3ai,YZn), (R1-3ai,YZo), (R1-3ai,YZp), (R1-3ai,YZq), (R1-3ai,YZr), (R1-3ai,YZs), (R1-3ai,YZt), (R1-3ai,YZu), (R1-3ai,YZv), (R1-3ai,YZw), (R1-3ai,YZx), (R1-3ai,YZy), (R1-3ai,YZz), (R1-3ai,YZaa), (R1-3ai,YZab), (R1-3ai,YZac), (R1-3ai,YZad), (R1-3ai,YZae), (R1-3ai,YZaf), (R1-3ai,YZag), (R1-3ai,YZah), (R1-3ai,YZai), (R1-3ai,YZaj), (R1-3ai,YZak), (R1-3ai,YZal), (R1-3ai,YZam), (R1-3ai,YZan), (R1-3ai,YZao), (R1-3ai,YZap), (R1-3ai,YZaq), (R1-3ai,YZar), (R1-3ai,YZas), (R1-3ai,YZat), (R1-3ai,YZau), (R1-3aj,YZa), (R1-3aj,YZb), (R1-3aj,YZc), (R1-3aj,YZd), (R1-3aj,YZe), (R1-3aj,YZf), (R1-3aj,YZg), (R1-3aj,YZh), (R1-3aj,YZi), (R1-3aj,YZj), (R1-3aj,YZk), (R1-3aj,YZl), (R1-3aj,YZm), (R1-3aj,YZn), (R1-3aj,YZo), (R1-3aj,YZp), (R1-3aj,YZq), (R1-3aj,YZr), (R1-3aj,YZs), (R1-3aj,YZt), (R1-3aj,YZu), (R1-3aj,YZv), (R1-3aj,YZw), (R1-3aj,YZx), (R1-3aj,YZy), (R1-3aj,YZz), (R1-3aj,YZaa), (R1-3aj,YZab), (R1-3aj,YZac), (R1-3aj,YZad), (R1-3aj,YZae), (R1-3aj,YZaf), (R1-3aj,YZag), (R1-3aj,YZah), (R1-3aj,YZai), (R1-3aj,YZaj), (R1-3aj,YZak), (R1-3aj,YZal), (R1-3aj,YZam), (R1-3aj,YZan), (R1-3aj,YZao), (R1-3aj,YZap), (R1-3aj,YZaq), (R1-3aj,YZar), (R1-3aj,YZas), (R1-3aj,YZat), (R1-3aj,YZau), (R1-3ak,YZa), (R1-3ak,YZb), (R1-3ak,YZc), (R1-3ak,YZd), (R1-3ak,YZe), (R1-3ak,YZf), (R1-3ak,YZg), (R1-3ak,YZh), (R1-3ak,YZi), (R1-3ak,YZj), (R1-3ak,YZk), (R1-3ak,YZl), (R1-3ak,YZm), (R1-3ak,YZn), (R1-3ak,YZo), (R1-3ak,YZp), (R1-3ak,YZq), (R1-3ak,YZr), (R1-3ak,YZs), (R1-3ak,YZt), (R1-3ak,YZu), (R1-3ak,YZv), (R1-3ak,YZw), (R1-3ak,YZx), (R1-3ak,YZy), (R1-3ak,YZz), (R1-3ak,YZaa), (R1-3ak,YZab), (R1-3ak,YZac), (R1-3ak,YZad), (R1-3ak,YZae), (R1-3ak,YZaf), (R1-3ak,YZag), (R1-3ak,YZah), (R1-3ak,YZai), (R1-3ak,YZaj), (R1-3ak,YZak), (R1-3ak,YZal), (R1-3ak,YZam), (R1-3ak,YZan), (R1-3ak,YZao), (R1-3ak,YZap), (R1-3ak,YZaq), (R1-3ak,YZar), (R1-3ak,YZas), (R1-3ak,YZat), (R1-3ak,YZau), (R1-3al,YZa), (R1-3al,YZb), (R1-3al,YZc), (R1-3al,YZd), (R1-3al,YZe), (R1-3al,YZf), (R1-3al,YZg), (R1-3al,YZh), (R1-3al,YZi), (R1-3al,YZj), (R1-3al, YZk), (R1-3al, YZl), (R1-3al, YZm), (R1-3al,YZn), (R1-3al,YZo), (R1-3al,YZp), (R1-3al,YZq), (R1-3al,YZr), (R1-3al,YZs), (R1-3al,YZt), (R1-3al, YZu), (R1-3al,YZv), (R1-3al,YZw), (R1-3al, YZx), (R1-3al,YZy), (R1-3al,YZz), (R1-3al, YZaa), (R1-3al,YZab), (R1-3al, YZac), (R1-3al, YZad), (R1-3al,YZae), (R1-3al,YZaf), (R1-3al,YZag), (R1-3al,YZah), (R1-3al,YZai), (R1-3al, YZaj), (R1-3al,YZak), (R1-3al,YZal), (R1-3al,YZam), (R1-3al,YZan), (R1-3al,YZao), (R1-3al,YZap), (R1-3al, YZaq), (R1-3al,YZar), (R1-3al,YZas), (R1-3al,YZat), (R1-3al,YZau), (R1-3am,YZa), (R1-3am,YZb), (R1-3am,YZc), (R1-3am,YZd), (R1-3am,YZe), (R1-3am,YZf), (R1-3am,YZg), (R1-3am,YZh), (R1-3am,YZi), (R1-3am,YZj), (R1-3am,YZk), (R1-3am,YZl), (R1-3am,YZm), (R1-3am,YZn), (R1-3am,YZo), (R1-3am,YZp), (R1-3am,YZq), (R1-3am,YZr), (R1-3am,YZs), (R1-3am,YZt), (R1-3am,YZu), (R1-3am,YZv), (R1-3am,YZw), (R1-3am,YZx), (R1-3am,YZy), (R1-3am,YZz), (R1-3am,YZaa), (R1-3am,YZab), (R1-3am,YZac), (R1-3am,YZad), (R1-3am,YZae), (R1-3am,YZaf), (R1-3am,YZag), (R1-3am,YZah), (R1-3am,YZai), (R1-3am,YZaj), (R1-3am,YZak), (R1-3am,YZal), (R1-3am,YZam), (R1-3am,YZan), (R1-3am,YZao), (R1-3am,YZap), (R1-3am,YZaq), (R1-3am,YZar), (R1-3am,YZas), (R1-3am,YZat), (R1-3am,YZau). In one embodiment, preferable acrylamide compounds are the compounds of the following Formula IA: wherein R1 and R2 are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted aryl; R3 and R4 are each independently hydrogen or optionally substituted alkoxy; W is —CH2—, m is 0 and n is 2; or W is —O—, m is 1 and n is 1; p is 0; Y is —S(O)2—; and Z is optionally substituted aryl. In another embodiment, preferable acrylamide compounds are the above compound IA wherein R1 and R2 are each independently hydrogen, cycloalkyl, cycloalkylalkyl or aryl; R3 and R4 are each independently hydrogen or alkoxy; W is —CH2—, m is 0 and n is 2; or W is —O—, m is 1 and n is 1; p is 0; Y is —S(O)2—; and Z is aryl optionally substituted with haloalkoxy. In another embodiment, preferable acrylamid compounds are the above compound IA wherein R1 and R2 are each independently hydrogen or cycloalkyl; R3 and R4 are each independently hydrogen or alkoxy; W is −CH2—, m is 0 and n is 2; or W is —O—, m is 1 and n is 1; p is 0; Y is —S(O)2—; and Z is aryl optionally substituted with haloalkoxy. The invention disclosed herein is also meant to encompass prodrugs of any of the disclosed compounds. As used herein, prodrugs are considered to be any covalently bonded carriers that release the active parent drug in vivo. In general, such prodrugs will be a functional derivative of a compound of Formula I, IA or IB which are readily convertible in vivo, e.g., by being metabolized, into the required compound of Formula I, IA or IB. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, NPL13; NPL14; NPL15; NPL16; NPL17; and NPL18. Non-limiting examples of prodrugs include esters or amides of compounds of Formula I, IA or IB having hydroxy or amino as a substituent, and these can be prepared by reacting such compounds with anhydrides such as succinic anhydride. The invention disclosed herein is also meant to encompass any of the disclosed compounds being isotopically-labelled (i.e., radiolabeled) by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively, and preferably 3H, 11C, and 14C. Isotopically-labeled compounds of the present invention can be prepared by methods known in the art. The present invention is also directed specifically to 3H, 11C, and 14C radiolabeled compounds of Formula I, IA or IB as well as their pharmaceutically acceptable salts, and solvates, and the use of any such compounds as radioligands for their binding site on the calcium channel. For example, one use of the labeled compounds of the present invention is the characterization of specific receptor binding. Another use of the labeled compounds of the present invention is an alternative to animal testing for the evaluation of structure-activity relationships. For example, the receptor assay may be performed at a fixed concentration of a labeled compound of Formula I, IA or IB and at increasing concentrations of a test compound in a competition assay. For example, tritiated compounds of any of Formula I, IA or IB can be prepared by introducing tritium into the particular compound
{'bibliographic_information': "{'country': 'US', 'doc-number': '13260185', 'kind': 'B2', 'date': '20100402', 'extension': '313', 'invention_title': 'Acrylamide compounds and the use thereof'}", 'source_file': './grant/2014/ipg141125.xml', 'source_data': 'USPTO-Grant'}